Molecular Cloning (Biomolecules production)
Design: depending on the customers‘ needs and protein characteristics (size, modifications, etc.) we identify the most appropriate expression system for recombinant protein production selecting between Escherichia coli, insect cells (with expression systems based on transient expression or by infection with recombinant baculovirus ) and mammalian cells.
Cloning: the recombinant gene for the protein of interest, once optimised for codon usage, is cloned into the selected expression vector. When necessary, affinity purification tags, solubilizing tags and/or secreting signal peptides are incorporated into the design.
Sequencing: all constructs are sequenced to verify the accuracy of the gene sequence.
Customer benefits
The service is completely personalised to ensure that the final construct matches the intended use for later protein production in the chosen expression system and further purification. Thus, instead of offering a generic solution, we deliver a customised product with the exact specifications requested by the customer.
Target customer
This Unit extends its services across the scientific community, serving both private and public research organizations. This includes support for research centres, universities, hospitals, and companies in the sector. Leveraging our connection with the university, the PPP unit also provides specialised courses as part of the official master’s degrees and PhD programs at UAB.
Additional information
Over its 17-year history, this unit has successfully completed over 400 projects and has been recognised in more than 121 scientific publications. In the past three years, it has received citations in the following works:
- ACS Materials Lett. 2024, 6, 3, 954–962
- Front. Immunol. 2024. 15:1346512.
- Applied Microbiology and Biotechnology (2024) 108:98
- ACS Sustainable Chem. Eng. 2023, 11, 4133−4144
- Pharmaceutics 2023, 15, 2632.
- Microbial Cell Factories (2023) 22:81
- Biomed Pharmacother 2023. 164:114976.
- ACS Appl. Mater. Interfaces 2023, 15, 39167−39175
- Pharmaceutics 2023, 15, 1197
- Sci China Mater 2023, 66(10): 4109–4120
- Pharmaceutics 2023, 15(3), 727
- Biomedicine & Pharmacotherapy 2023, 169(1):115848
- Appl Environ Microbiol 2023 Jun 28;89(6)
- Biomedicine & Pharmacotherapy 150 (2022) 112940
- Biomaterials 280 (2022) 121258
- Pharmaceutics 2022, 14, 887
- J. Exp Clin Cancer Res (2022) 41:49
- DRUG DELIVERY 2022, VOL. 29, NO. 1, 1384–1397
- Biomedicines 2022, 10, 1680.
- Microbial Cell Factories (2022) 21:203
- Acta Pharmaceutica Sinica B 2022;12(5):2578e2591
- Pharmaceutics 2022, 14, 602.
- Pharmaceutics 2022, 14, 192.
- Front. Bioeng. Biotechnol. 2022 10:842256.
- Anal. Chem. 2022, 94, 5359−5366
- Odontology (2022) 110:545–556